GILD
Gilead Sciences, Inc.
NASDAQ · USHealthcareDrug Manufacturers - General
$133.21-0.80%
Price as of Jul 20, 2026
GILD profitability
Gilead Sciences, Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 79.4%
- EBITDA margin
- 47.1%
- EBIT margin
- 38.3%
- Net margin
- 31.0%
- Free cash flow margin
- 34.4%
Returns
- Return on equity
- 39.2%
- Return on assets
- 16.4%
- Return on invested capital
- 24.9%
- Asset turnover
- 0.52x
Cash efficiency
- Cash from operations
- $10.8B
- Cash per share
- $7.91
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.